C WorldWide Group’s Acadia Pharmaceuticals ACAD Stock Holding History

C WorldWide Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-7,943	Closed	-$128K	–	114
2018 Q4	$128K	Sell	7,943 -204	-3%	-$3.96K	﹤0.01%	120
2018 Q3	$169K	Buy	8,147 +1,115	+16%	+$17.5K	﹤0.01%	129
2018 Q2	$107K	Hold	7,032	–	–	﹤0.01%	128
2018 Q1	$158K	Sell	7,032 -222	-3%	-$6.15K	﹤0.01%	122
2017 Q4	$218K	Sell	7,254 -1,007	-12%	-$32.2K	﹤0.01%	115
2017 Q3	$311K	Buy	8,261 +1,320	+19%	+$42.9K	﹤0.01%	117
2017 Q2	$194K	Sell	6,941 -564	-8%	-$16.8K	﹤0.01%	122
2017 Q1	$258K	Sell	7,505 -679	-8%	-$24K	﹤0.01%	116
2016 Q4	$236K	Sell	8,184 -12,206	-60%	-$323K	﹤0.01%	114
2016 Q3	$649K	Hold	20,390	–	–	0.01%	114
2016 Q2	$662K	Hold	20,390	–	–	0.01%	102
2016 Q1	$570K	Hold	20,390	–	–	0.01%	110
2015 Q4	$727K	Hold	20,390	–	–	0.01%	119
2015 Q3	$674K	Sell	20,390 -69,535	-77%	-$2.89M	0.01%	120
2015 Q2	$3.77M	Hold	89,925	–	–	0.05%	70
2015 Q1	$2.93M	Sell	89,925 -5,000	-5%	-$172K	0.04%	71
2014 Q4	$3.01M	Buy	+94,925	New	+$2.69M	0.04%	61

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

C WorldWide Group's ACAD Position: Q1 2019 in Review

C WorldWide Group sold out of Acadia Pharmaceuticals (ACAD) in Q1 2019, closing a stake of 7,943 shares — an estimated $128K sold.

C WorldWide Group first reported a position in ACAD in Q4 2014 and held it in 17 quarters. The position peaked at $3.77M in Q2 2015. 199 funds tracked by Wall St. Rank hold ACAD as of Q1 2019.

C WorldWide Group reported no remaining Acadia Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
C WorldWide Group sold 7,943 Acadia Pharmaceuticals shares in Q1 2019, an estimated $128K.
C WorldWide Group first reported a position in Acadia Pharmaceuticals in Q4 2014 and held it in 17 quarters.
C WorldWide Group's Acadia Pharmaceuticals position peaked at $3.77M in Q2 2015.
199 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2019.

Based on C WorldWide Group's 13F filing for Q1 2019, filed 3 May 2019.